Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619009 | 0.84 | ALDH1A1 (0.73) | ALDH1A1TDP1L3MBTL1GFERKDM4E | |
| SCHEMBL5895082 | 0.84 | ALDH1A1 (0.73) | ALDH1A1TDP1L3MBTL1KDM4ERAB9A | |
| SCHEMBL18015824 | 0.84 | ALDH1A1 (0.73) | ALDH1A1TDP1L3MBTL1GFERKDM4E | |
| SCHEMBL18015816 | 0.81 | L3MBTL1 (0.69) | ALDH1A1TDP1L3MBTL1KDM4ERAB9A | |
| SCHEMBL5930632 | 0.81 | ALDH1A1 (0.69) | ALDH1A1TDP1L3MBTL1GFERKDM4E | |
| SCHEMBL16619626 | 0.81 | L3MBTL1 (0.69) | ALDH1A1TDP1L3MBTL1KDM4ENPC1 | |
| SCHEMBL28247074 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TDP1L3MBTL1GFERKDM4E | |
| SCHEMBL28008732 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TDP1L3MBTL1GFERKDM4E | |
| SCHEMBL21115997 | 0.80 | ALDH1A1 (0.67) | ALDH1A1TDP1L3MBTL1KDM4ERAB9A | |
| SCHEMBL18014690 | 0.80 | ALDH1A1 (0.67) | ALDH1A1TDP1L3MBTL1GFERKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531688-A | Process for the preparation of L-alanyl-L-alanine 2- {4- [2- ({ [2 (4-chlorophenyl) -1, 3-thiazol-4-yl ] methyl } sulfanyl) -3, 5-dicyano-6- (pyrrolidin-1-yl) pyridin-4-yl ] phenoxy } ethyl ester monohydrochloride | 拜耳制药股份公司 | 2018-01-02 | — | — | CN | claimed |
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| CN-100475810-C | Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| CN-1678596-A | Novel 2-arylthiazole compounds as PPAR alpha and PPAR gamma agonists | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | CN | disclosed |
| US-6933322-B2 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2005-08-23 | — | — | US | disclosed |
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH | 2003-11-20 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | ALDH1A1 536/4885TDP1 4018/4885L3MBTL1 931/4885 |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | ALDH1A1 671/4885TDP1 4503/4885L3MBTL1 4589/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | ALDH1A1 671/4885TDP1 4503/4885L3MBTL1 4589/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | ALDH1A1 274/4885TDP1 1466/4885L3MBTL1 2050/4885 |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | INSR, GPR119, SLC5A1 | ALDH1A1 648/4885TDP1 3476/4885L3MBTL1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.